Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• BRAF(V600E) mutant melanomas initially respond to vemurafenib.
• Acquired resistance to vemurafenib limits long-term patient benefit.
• Understanding resistance mechanisms is crucial for improving melanoma treatment.

Purpose of the Study:

• To investigate mechanisms of acquired resistance to vemurafenib in BRAF(V600E) melanoma.
• To identify molecular alterations driving vemurafenib resistance.
• To evaluate combination therapies for overcoming vemurafenib resistance.

Main Methods:

• Establishment of vemurafenib-resistant BRAF(V600E) melanoma clones via chronic selection.
• Analysis of BRAF coding sequence for mutations.
• Assessment of extracellular signal-regulated kinase (ERK) phosphorylation and RAS-GTP levels.
• Sequencing of RAS genes to identify mutations.
• Evaluation of combination treatments with vemurafenib and MEK or AKT inhibitors.

Main Results:

• Resistant clones retained the BRAF(V600E) mutation without secondary mutations in BRAF.
• Vemurafenib failed to inhibit ERK phosphorylation, indicating pathway reactivation.
• Resistance correlated with increased RAS-GTP levels, including a novel KRAS K117N mutation.
• Elevated CRAF and phosphorylated AKT levels were observed in resistant cells.
• Combination therapy with vemurafenib and MEK or AKT inhibitors synergistically reduced proliferation.

Conclusions:

• Acquired resistance to vemurafenib in melanoma involves reactivation of the RAS/RAF pathway.
• Mechanisms include elevated RAS-GTP, KRAS mutations, and increased AKT phosphorylation.
• Combination targeted therapies are a promising strategy to combat vemurafenib resistance.